PKC (protein kinase C) isoenzymes are related protein kinases, involved in many signalling events in normal state and in disease. Basic research into identifying the molecular basis of PKC selectivity led to simple strategies to identify selective competitive inhibitor peptides and allosteric agonist peptides of individual PKC isoenzymes. The strategies and rationale used to identify these peptide regulators of protein-protein interaction may be applicable to other signalling events. Importantly, the PKC-regulating peptides proved to be useful pharmacological tools and may serve as drugs or drug leads for a variety of human diseases.
Introduction
PKC (protein kinase C) isoenzymes constitute a family of homologous serine/threonine kinases that are involved in many signalling events [1, 2] . Their roles in pathological conditions including cancer [3] , pain sensation [4] , diabetes [5, 6] , heart attack [7, 8] , stroke [9, 10] , heart failure [11] , angiogenesis [12] and regulation of the immune response [13] have been identified over the last 30 years, and several pharmaceutical companies have engaged in the development of selective inhibitors for these enzymes [14] . However, generating PKC isoenzyme-selective inhibitors that target the active enzyme has proven to be a challenge.
The role of subcellular location in PKC signalling
The basic research in our laboratory did not aim to develop isoenzyme-selective pharmacological reagents. Rather, we were puzzled by the observation that multiple isoenzymes are present in the same cells and are stimulated by the same hormones, growth factors and neurotransmitters. Although in vitro the isoenzymes have similar substrate selectivity [15] , we expected that each of the isoenzymes has different roles. In 1987, we began to find that the subcellular localization of individual isoenzymes before and after activation is unique [16] and suggested that functional selectivity of individual isoenzymes is determined by their subcellular location. We proposed that there must be proteins that anchor each isoenzyme at unique subcellular sites and called these proteins RACKs (receptors for activated C-kinase). RACKs were Key words: allosteric agonist, C2 domain, inhibitor peptide, protein kinase C isoenzyme (PKC isoenzyme), protein-protein interaction, receptor for activated C-kinase (RACK). Abbreviations used: AUC, area under the curve; CK-MB, creatine kinase muscle/brain type; MI, myocardial infarction; PKC, protein kinase C; RACKs, receptors for activated C-kinase. 1 To whom correspondence should be addressed (email mochly@stanford.edu).
subsequently purified [17] and cloned [18, 19] (see Figure 1 ). To further confirm the importance of the interaction of an individual isoenzyme with its RACK, we next sought to generate selective inhibitors and activators of these interactions.
Rationale of design of isoenzyme-specific competitive inhibitors of PKC signalling
When we began that project, high-throughput screens were not available; instead we were aided by an observation made by Alistair Aitken that 14-3-3, a protein he found to inhibit PKC [20] , and annexin I, a protein we found to bind βPKC [17] , share a 12-amino-acid sequence of homology. We reasoned that, since these otherwise unrelated proteins both bind PKC, perhaps the sequence of homology mediates PKC binding to these two proteins. We then showed that a peptide corresponding to this sequence (peptide I) inhibits PKC binding to the purified or cloned RACK, as well as to annexin I [21] . Importantly, this peptide inhibits β II PKC function in cells; injection into Xenopus oocyte inhibits insulin-induced oocyte maturation [22] .
Obviously, the finding that a linear peptide inhibits protein-protein interactions in vitro and in vivo was surprising; we expected limited structure conservation in this short peptide, relative to the whole protein. Furthermore, proteinprotein interactions are notoriously difficult to inhibit [23] ; the sites are thought to be relatively flat, without an identifiable druggable pocket. Nevertheless, the first success with peptide I guided us to continue with the approach, especially because after we cloned the β II PKC RACK, we found a peptide I homologue in RACK1, and a peptide corresponding to this peptide inhibits its interaction with PKC [24] .
We next reasoned that peptides derived from PKC might also inhibit PKC binding to its RACK. Here, we were guided by another logic: at the time, there were a number of signalling Upon stimulation, inactive PKC translocates to its corresponding isoenzyme-specific subcellular location to phosphorylate location-specific downstream substrates. The destination of subcellular translocation is determined by the location of the RACKs, which provide the isoenzyme-specific anchor and scaffold for the catalytic function.
proteins that 'translocated' or moved from the soluble fraction to the cell particulate fraction following cell stimulation. These enzymes included phospholipase C, phospholipase D and also the synaptic vesicle-specific protein, synaptotagmin (also called p65). These proteins all have a ∼ 150-amino-acid domain, which is homologous with the second common domain (C2) in PKC [25, 26] . We suggested that the C2 domain anchors these translocating proteins following cell stimulation (the C2 domains were already known to bind lipids at that time, but the possibility that they were involved in protein-protein interactions had not been examined). To determine whether the C2 domain mediates anchoring, we first used recombinant synaptotagmin C2 domains and demonstrated that they can also bind to RACK, albeit with about one-hundredth the affinity [27] . We then reasoned that peptides corresponding to the most homologous regions between βPKC C2 and synaptotagmin C2 may correspond to the interaction sites between each protein and its respective anchoring protein. Subsequent studies using short peptides derived from the C2 domain confirmed these findings [28, 29] . These peptides act as competitive antagonists of PKC-RACK interaction (see Figure 2) .
The novel PKC isoenzymes have a C2-like domain, initially called the V1 region [30] . Publications by Sossin and Schwartz [31, 32] reported that the sea snail, Aplysia californica, has an εPKC-like isoenzyme and that the V1 region in that isoenzyme is homologous with the C2 domain. Subsequent studies showed that, as in the classical PKC isoenzymes, the C2-like domain of the novel PKCs also mediates, at least in part, the anchoring of these isoenzymes with their RACKs [33] . By comparing the evolutionary remote Aplysia and rat sequences in the C2 domain, we reasoned that the most similar sequences are likely to mediate the interaction of εPKC with its RACK. This was confirmed; a peptide derived from amino acids 14-21 (εV [1] [2] ) is a selective inhibitor of εPKC translocation and functions [33, 34] . Selective antagonists for the δPKC and θPKC were designed based on the least homologous sequences in the C2 domain of these highly homologous isoenzymes [35] .
An isoenzyme-selective competitive inhibitor of δPKC tested in clinical trials
The peptide inhibitor for δPKC, δV 1-1 , has just completed Phase IIa clinical trials in patients with acute MI (myocardial infarction). Animal studies showed that the peptide is safe in a wide range of concentrations and that delivering the peptide after MI or stroke reduces infarct size by ∼ 70% and reduces functional impairments of both organs [36, 37] . These results led to the first in-human double-blind trial (conducted by KAI Pharmaceuticals), in which the inhibitor (aka KAI-9803) did not cause adverse effects. Although the trial was not powered to show statistical significance (it included four different cohorts and multiple end points of analysis), the results were encouraging: there were no signs of adverse effects (6% death in placebo and 3% death in drug-treated), and across all dosing cohorts, CK-MB (creatine kinase muscle/brain type) AUC (area under the curve), CK-MB estimated peak and ST segment recovery AUC values were reduced [38] .
Peptides derived from the PKC-cognate proteins are also useful competitive inhibitors of PKC signalling
It was clear that many other intermolecular interactions between each PKC isoenzyme and its cognate proteins must exist and that not all are mediated through the C2 domain. In a recent review, some of these interactions are discussed [39] . Further, because β I PKC and β II PKC differ only in their last 50 amino acids [25] in the V5 domain, and each isoenzyme is mediating unique functions, it was clear that the V5 domain plays a critical role in protein-protein interactions. Parker and co-workers [40] and Newton and co-workers [41] demonstrated that key phosphorylation events occur in that region and these phosphorylations specify maturation/activation of the enzyme. This region also mediates unique lipid interactions [42] as well as interaction with the corresponding RACKS and other interaction proteins [43] . Peptides derived from β II PKC and not β I PKC inhibit the interaction between β II PKC and RACK1 [44] and the interaction of β I PKC and not β II PKC with RBCK1 [RING-B box-coiled-coil (RBCC) protein interacting with PKC 1] [45] and the subsequent function of these isoenzymes in cardiac hypertrophy [45] .
Rationale of design of isoenzyme-specific allosteric agonists of PKC signalling
The rationale to identify allosteric agonist peptides stemmed from the observation by House and Kemp [46] that, in the inactive state, PKC is engaged in intramolecular autoinhibitory interactions. These interactions were mediated between the active site of the enzyme and a sequence in the regulatory domain that was similar to a phosphorylation site, and was thus termed the pseudosubstrate site [46] . We hypothesized that similar to the pseudosubstrate site, there must be a pseudo-RACK site. Homology search between RACK1 and its cognate isoenzyme, β II PKC, and between RACK2 and its cognate isoenzyme, εPKC, yielded short sequences of homology of six and eight amino acids respectively between each pair of unrelated gene products [24, 47] . Peptides corresponding to these sequences are selective activators of βIIPKC and εPKC respectively [24, 47] . These allosteric agonist peptides, and the sequences from which they are derived (Figure 3) , differ in charge from the PKC-binding site on the RACK (lysine to glutamic acid in the allosteric agonist of β II PKC and asparagine to aspartic acid in the allosteric agonist of εPKC). We predicted that this charge difference is important to enable the disruption of the intramolecular, lower affinity interaction with the intermolecular interaction between the isoenzyme and its RACK (reviewed in [48] ). Indeed, reversal of the charge in the peptide allosteric agonist converted it into an antagonist [49] , and a charge mutation in the enzyme at the pseudo-RACK site slowed down its activation process [50] . We therefore conclude that the allosteric agonist stabilizes a transiently formed open conformation of the enzyme, in which the intramolecular autoinhibitory interactions are disrupted. The agonist is thought to leave the kinase once the enzyme binds the RACK [22, 47, 48] .
The search of pseudo-interaction site between PKC and other interacting proteins also yielded an inhibitor of δPKC that is derived from annexin V, a δPKC-specific binding protein [51] . We showed that a six-amino-acid peptide derived from a sequence in annexin V that differs in one charge from a homologous sequence in δPKC inhibits its binding to Protection from ischaemic injury [51] annexin V and subsequent translocation to this site of action [51] . As for the allosteric agonist, conversion of the peptide into a sequence more similar to the δPKC-derived sequence (an arginine to glutamic acid) caused a loss of the inhibitory activity of the peptide [51] . The use of this peptide elucidated a new step early in PKC translocation that is energy-and microtubule-dependent that occurs prior to anchoring of the active enzyme at its subcellular site of action. Importantly, like δV1-1, the annexin V-derived peptide inhibited reperfusion injury to the heart after ischaemia [51] .
Unbiased scan for additional protein-protein interaction sites in the C2 domain
Review of the literature made it clear that, in addition to binding RACKs, many other proteins interact with PKC in general, and with the C2 domain in particular [39] . We predict that even for the C2 domain, at least some of the binding sites for individual proteins are distinct; i.e. different proteins interact with a different part of the domain. We therefore synthesized ∼ 15 peptides that cover most of the C2 domain of εPKC and tested them in four biological-based assays. Four of the peptides were antagonists, six peptides were selective agonists of εPKC and the remaining peptides activate or inhibit several PKC isoenzymes, presumably by affecting sites of interaction that are common in the C2 domain [52] . Current studies examine our hypothesis regarding the potential selectivity of these C2-derived peptides to subsets of protein-protein interactions.
Delivery of peptides into cells
How are the peptides introduced across biological membranes? In our initial studies, we injected the peptides [21] , transiently permeabilized the cells in the presence of the peptides [53] , and expressed the peptides as transgenes [35, 47] . However, the peptides can easily cross biological membranes by cross-linking them to a number of cell-permeable peptides including those derived from antennapedia [54] , Tat (transactivator of transcription) [55] and even a short polyarginine peptide [56] , all with similar effects [56] . This converted the peptide regulators of PKC into simple pharmacological tools that can be used in culture and in vivo, in fact already in humans [38] .
Summary
It is clear that the cell requires the orchestration of many intracellular protein-protein interactions to optimize signal transduction. It also appears that the lessons we have learned about drug design have focused predominantly on extracellular signalling events, mainly inhibiting ligand-receptor interactions. Regulation of intracellular interactions (both by activating them with allosteric agonists and inhibiting them with competitive inhibitors, at least for the PKC-mediated signalling) was made possible using a simple approach to identify the interaction sites between the proteins. These regulators, short peptides, have been proven to be useful pharmacological and research tools in our laboratory and the laboratories of others ( Table 1 ). The peptides have provided tremendous insight into the role of individual PKC isoenzymes in normal and disease states; we found that isoenzymes activated by the same signalling can have the same [44] , different or even opposing [35] functions. Using both inhibitors and activators of the same isoenzyme, we could also determine whether the isoenzyme is both required and sufficient for the function tested [35] . It is our hope that the approach can be adopted for the study of other signalling events and that these peptides will serve as therapeutics or at least as lead compounds to develop drugs to many unmet needs.
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